Estrella Immunopharma Inc. Cash Flow-to-Debt Ratio
Estrella Immunopharma Inc. cash flow-to-debt ratio. Estrella Immunopharma Inc. (ESLA) has a Cash Flow-to-Debt Ratio of -0.19x as of June 2026, meaning its operating cash flow of $-1.78 Million could theoretically repay 0% of its total liabilities ($9.26 Million) in one year. See Estrella Immunopharma Inc. (ESLA) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Estrella Immunopharma Inc. (2021–2025)
Cash flow-to-debt ratio of Estrella Immunopharma Inc. from 2021 to 2025. Historical debt coverage capacity for Estrella Immunopharma Inc. across 5 annual periods. Also explore ESLA net asset momentum to track the company's year-over-year net asset growth rate.
Estrella Immunopharma Inc. Cash Flow-to-Debt Ratio by Year (2021–2025)
Estrella Immunopharma Inc. cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Estrella Immunopharma Inc.. For the full cash flow conversion analysis, see Estrella Immunopharma Inc. cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.13x | $-1.79 Million | $13.54 Million | ▲ +87.3% |
| 2024 | -1.04x | $-3.11 Million | $3.00 Million | ▲ +98.8% |
| 2023 | -88.92x | $-16.07 Million | $180.70K | ▼ -24738.1% |
| 2022 | -0.36x | $-1.04 Million | $2.92 Million | ▼ -48.0% |
| 2021 | -0.24x | $-1.44 Million | $5.96 Million | — |